Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naroa Serna

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Human Molecular Genetics|August 8, 2018
Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyriaIrantzu Serrano-Mendioroz, Ana Sampedro, Naroa Serna, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 10, 2020
Release of functional fibroblast growth factor-2 from artificial inclusion bodiesNaroa Serna, Olivia Cano-Garrido, Julieta M Sánchez, et al.
Pharmaceutics|November 27, 2021
Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4Naroa Serna, José Vicente Carratalá, Oscar Conchillo-Solé, et al.
Small (Weinheim an Der Bergstrasse, Germany)|June 25, 2020
Engineering Protein Nanoparticles Out from Components of the Human MicrobiomeHèctor López-Laguna, Laura Sánchez-García, Naroa Serna, et al.
Pharmaceutics|December 22, 2020
In Vivo Bactericidal Efficacy of GWH1 Antimicrobial Peptide Displayed on Protein Nanoparticles, a Potential Alternative to AntibioticsJose V Carratalá, Eric Brouillette, Naroa Serna, et al.
Acta Biomaterialia|September 9, 2019
Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4<sup>+</sup> colorectal cancerRita Sala, Laura Sánchez-García, Naroa Serna, et al.
Pharmaceutics|January 21, 2022
Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid MaterialsNaroa Serna, Aïda Falgàs, Annabel García-León, et al.
ACS Applied Materials & Interfaces|December 16, 2020
Developing Protein-Antitumoral Drug Nanoconjugates as Bifunctional Antimicrobial AgentsNaroa Serna, Jose Vicente Carratalá, Eloi Parladé, et al.
Acta Biomaterialia|September 8, 2023
High-precision targeting and destruction of cancer-associated PDGFR-β<sup>+</sup> stromal fibroblasts through self-assembling, protein-only nanoparticlesEric Voltà-Durán, Lorena Alba-Castellón, Naroa Serna, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 5, 2023
Lymphocyte infiltration and antitumoral effect promoted by cytotoxic inflammatory proteins formulated as self-assembling, protein-only nanoparticlesCarlos Martínez-Torró, Lorena Alba-Castellón, Luis Miguel Carrasco-Díaz, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Human Molecular Genetics|August 8, 2018
Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyriaIrantzu Serrano-Mendioroz, Ana Sampedro, Naroa Serna, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 10, 2020
Release of functional fibroblast growth factor-2 from artificial inclusion bodiesNaroa Serna, Olivia Cano-Garrido, Julieta M Sánchez, et al.
Pharmaceutics|November 27, 2021
Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4Naroa Serna, José Vicente Carratalá, Oscar Conchillo-Solé, et al.
Small (Weinheim an Der Bergstrasse, Germany)|June 25, 2020
Engineering Protein Nanoparticles Out from Components of the Human MicrobiomeHèctor López-Laguna, Laura Sánchez-García, Naroa Serna, et al.
Pharmaceutics|December 22, 2020
In Vivo Bactericidal Efficacy of GWH1 Antimicrobial Peptide Displayed on Protein Nanoparticles, a Potential Alternative to AntibioticsJose V Carratalá, Eric Brouillette, Naroa Serna, et al.
Acta Biomaterialia|September 9, 2019
Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4<sup>+</sup> colorectal cancerRita Sala, Laura Sánchez-García, Naroa Serna, et al.
Pharmaceutics|January 21, 2022
Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid MaterialsNaroa Serna, Aïda Falgàs, Annabel García-León, et al.
ACS Applied Materials & Interfaces|December 16, 2020
Developing Protein-Antitumoral Drug Nanoconjugates as Bifunctional Antimicrobial AgentsNaroa Serna, Jose Vicente Carratalá, Eloi Parladé, et al.
Acta Biomaterialia|September 8, 2023
High-precision targeting and destruction of cancer-associated PDGFR-β<sup>+</sup> stromal fibroblasts through self-assembling, protein-only nanoparticlesEric Voltà-Durán, Lorena Alba-Castellón, Naroa Serna, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 5, 2023
Lymphocyte infiltration and antitumoral effect promoted by cytotoxic inflammatory proteins formulated as self-assembling, protein-only nanoparticlesCarlos Martínez-Torró, Lorena Alba-Castellón, Luis Miguel Carrasco-Díaz, et al.
Pageof 6